LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Publisher: Taylor & Francis
Languages: English
Types: Article
Subjects: RS, RM

Classified by OpenAIRE into

mesheuropmc: lipids (amino acids, peptides, and proteins)
The present article is aimed to outline the current state of knowledge regarding the effects of lipoprotein(a) (Lp(a)) on cardiovascular disease (CVD) risk by summarizing the recent results of studies, meta-analyses and systematic reviews. The literature supports the predictive value of Lp(a) on CVD outcomes, although the effect size is modest. Lp(a) would also appear to have an effect on cerebrovascular outcomes, with the effect appearing even smaller than that for CVD outcomes. Consideration of apolipoprotein apolipoprotein(a) (apo (a)) isoforms and LPA genetics in relation to the simple assessment of Lp(a) concentration may enhance improving clinical practice in vascular medicine. We also describe recent advances in Lp(a) research (including therapies) and highlight areas where further research is needed such as the measurement of Lp(a) and its involvement in additional pathophysiological processes.
  • No references.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article